Hyperactivity disorder (HDD), is a growing concern in the literature. The global burden of ADHD is estimated at $11.5 billion and is estimated to increase by 20% annually by 2030 [
,
]. The rising incidence of ADHD is a result of rising awareness of the condition, improved public health, and a greater awareness of the need to treat this condition with more and more effective therapies [
The most effective treatment for ADHD involves the use of medications, often referred to as “stimulants” [
Stimulants are a class of non-stimulant medications used to treat attention deficit hyperactivity disorder (ADHD) in adults. They can be used off-label for ADHD, such as in the treatment of narcolepsy [
Stimulants are not considered to be effective in the management of ADHD [
The efficacy of stimulants has been demonstrated in several studies, particularly in the treatment of ADHD [
The mechanism of action of these medications has been to alter the brain’s dopamine and norepinephrine neurotransmitters, leading to increased levels of these neurotransmitters [
Stimulant treatment for ADHD often involves the administration of medication, either alone or with other medications, for an extended period. This is the primary mechanism of action of stimulant medications, which may be used in combination with other medications to improve treatment outcomes [
However, the efficacy and safety of stimulant medications are still being researched, and there is a need to develop new therapies for ADHD.
The efficacy of stimulant medications has been demonstrated in several studies, including in the treatment of ADHD [
In one of these studies, the effectiveness of using a stimulant drug for ADHD was evaluated in a patient population of 50–80% of patients, and compared with placebo. The average response rate was 70% (mean 60.4%). The number needed to treat (NNT) was 8.5, and the number needed to achieve a response rate was 5.8 (mean 3.2). No statistically significant differences in response rates were found between stimulant medications. However, more than one medication was administered to a patient with ADHD, and the response rate was higher when the medication was combined with a stimulant drug [
In another study, the efficacy of a treatment with a selective norepinephrine reuptake inhibitor (SNRI) to treat ADHD was evaluated in a group of 40 patients, and compared with placebo. The response rates were 70% (mean 60.6%) and 64.3% (mean 60.2%), respectively, compared with placebo. The treatment was well tolerated, and there was no significant difference in the number needed to achieve a response rate between the groups. In addition to the efficacy studies, the safety profile of stimulant medications has been evaluated in a larger population, and the most commonly used is the use of a selective norepinephrine reuptake inhibitor (SNRI) to treat ADHD. There are several studies that compared the efficacy and safety of a stimulant drug and norepinephrine reuptake inhibitor (SNRI) to other medications in the treatment of ADHD [
In a study in 696 patients with ADHD who were prescribed stimulants, the mean response rate of the first week was 90.2% (mean 90.2%), and the mean response rate after 1 week was 84.4% (mean 84.2%). Patients who were prescribed stimulant medications and norepinephrine reuptake inhibitors (NRI) were more likely to have improved ADHD symptoms, but the rate of symptom improvement was less than in the other groups. There were no differences in the response rates between the groups.
The safety profile of the use of stimulant medications is not well-studied, and there is a need to develop new treatments for ADHD.
The efficacy of medications for ADHD has been demonstrated in several studies, including in the treatment of ADHD.
Sold and Supplied by Healthylife Pharmacy
This product is a Prescription Only Medicine (S4) and is sold by Healthylife Pharmacy, an independently owned and operated pharmacy business. This prescription product requires a valid Australian script.
Medicare CardNo MedicareConcession
$11.95
Healthylife provides general product information such as nutritional information, country of origin and product packaging for your convenience. This information is intended as a guide only, including because products change from time to time. Please read product labels before consuming. For therapeutic goods, always read the label and follow the directions for use on pack. If you require specific information to assist with your purchasing decision, we recommend that you contact the manufacturer via the contact details on the packaging or email us at [email protected]. Product ratings and reviews are taken from various sources including Bazaarvoice. Healthylife does not represent or warrant the accuracy of any statements, claims or opinions made in product ratings and reviews.
Prices$14.95
Healthylife provides complete product information, prescription waiver programs, and discounts for name-brand medicines, generic medicines, and administrative items
Healthylife offers free delivery for all products listed below.
Sold and Supplied by Healthylife Pharmacy
This product is a Prescription Only Medicine (S4) and is sold by Healthylife Pharmacy, an independently owned and operated pharmacy business. This prescription product requires a valid Australian script.
Healthylife provides general product information such as nutritional information, country of origin and product packaging for your convenience. This information is intended as a guide only, including because products change from time to time. Please read product labels before consuming. For therapeutic goods, always read the label and follow the directions for use on pack. If you require specific information to assist with your purchasing decision, we recommend that you contact the manufacturer via the contact details on the packaging or email us at [email protected]. Product ratings and reviews are taken from various sources including Bazaarvoice. Healthylife does not represent or warrant the accuracy of any statements, claims or opinions made in product ratings and reviews.
Atomoxetine (Strattera) 20 mgThis is a Prescription Only Medicine (S4) and is sold by Healthylife Pharmacy, an independently owned and operated pharmacy business. Keep all medicines out of the reach of children. Never share your medicines with anyone. This includes generic and non-prescription products. This does not affect the content of thisgently posted review.
Healthylife has helped thousands of people access caring advice and quality care. Their expertise has helped them to make informed decisions about their loved ones. Healthylife has a deep commitment to providing quality, compassionate healthcare. Take our service today to access the care you deserve. - Alison
This prescription only medicine requires a prescription.Atomoxetine (Strattera) is a selective norepinephrine reuptake inhibitor (SNRI) that is primarily used to treat symptoms of depression, anxiety disorders and attention-deficit hyperactivity disorder (ADHD). It works by increasing the levels of norepinephrine in the brain. Lower levels of norepinephrine cause decreased attention and impulse control, leading to improved emotional regulation and reduced hyperactivity in the brain. Atomoxetine is also thought to improve the quality of life for those affected by these disorders. It is also sometimes used to treat schizophrenia, bipolar disorder, and major depressive disorder.
Atomoxetine (Strattera) is an antidepressant that is primarily used to treat symptoms of depression, anxiety disorders and attention-deficit hyperactivity disorder (ADHD). Atomoxetine is also sometimes used to treat schizophrenia, bipolar disorder, and major depressive disorder. However, this is not always the case, and there are some safety concerns associated with this medication that may deter some patients from using this medication.
Adults:At Attention Deficit Hyperactivity Disorder (ADHD)span use: amphetamine (amphetamine) or diclofenac sodium (SNRI). Children: Adults: T. I. TitratedChildren: As appropriate: T. (At Attention Deficit Hyperactivity Disorder) (2013–2017)T. Treatment of ADHD in children <25 years: A new pharmacological treatment guideline. J Child Adolesc Psychiatry, Vol. 40, Issue 3, July 2013, pp. 101-120.
Strattera: Atomoxetine (At Attention Deficit Hyperactivity Disorder) (2014)ADHD stimulant: Atomoxetine (At Attention Deficit Hyperactivity Disorder) (2015)stimulant in treatment of ADHD in children: Atomoxetine (At Attention Deficit Hyperactivity Disorder) (2016)stimulant in treatment of ADHD in children: Atomoxetine (At Attention Deficit Hyperactivity Disorder) (2017)Adults: T. (At Attention Deficit Hyperactivity Disorder) (2013)Children and adolescents: Atomoxetine (At Attention Deficit Hyperactivity Disorder) (2013)Children and adolescents: T.Children and adolescents: Adults: Atomoxetine (At Attention Deficit Hyperactivity Disorder) (2016)Adults: Adults: T. (At Attention Deficit Hyperactivity Disorder) (2011)Children and adolescents: Adults: Atomoxetine (At Attention Deficit Hyperactivity Disorder) (2010)(At Attention Deficit Hyperactivity Disorder) (2008)Children and adolescents: Adults: Atomoxetine (At Attention Deficit Hyperactivity Disorder) (2008)(At Attention Deficit Hyperactivity Disorder) (2006)Children and adolescents: Adults: T. (At Attention Deficit Hyperactivity Disorder) (2004)Adults: Adult: T. (At Attention Deficit Hyperactivity Disorder) (1992)Adult/Adult: Atomoxetine (At Attention Deficit Hyperactivity Disorder) (1992)Children and adolescents: Atomoxetine (At Attention Deficit Hyperactivity Disorder) (1992)Children and adolescents: Adults: Atomoxetine (At Attention Deficit Hyperactivity Disorder) (1992)Adult/Adult: Adults: T.
Atomoxetine HCL, commonly known by its brand name Strattera, is a non-stimulant medication prescribed to treat Attention-Deficit Hyperactivity Disorder (ADHD). It works by increasing the levels of norepinephrine in the brain, which helps improve attention, focus, and impulse control[2].
The global Atomoxetine HCL API market is experiencing significant growth, driven by several key factors:
The innovative and-in-OTH/Orthopaedic-Biological-Pharmaceutical-Medications (OFPM) segment is segmented by type, with strength markers:Innovative Pharmaceuticals: These are developed by Johnson & Johnson and are representative of various OFPMs used for the treatment of ADHD[2].
The global Atomoxetine HCL API market is projected to grow at a Compound Annual Growth Rate (CAGR) of 5.00% from 2024 to 2031[1].
The global Atomoxetine HCL industry is focus-based, with potential formulations:: These are developed by manufacturers of various formulations, including OFPMs, used for the treatment of ADHD[2].
The market is analyzed in detail in the following regions:
As with any medication, there are potential side effects associated with Atomoxetine HCL:
The global Atomoxetine HCL market is expected to grow at a CAGR of 5.00% from 2024 to 2031� and USDxxx million by 2031[1].
There are several - among the most important - currently available - for Atomoxetine HCL:
Stade de France Pharmacy